Senator Bernie Sanders Challenges Novo Nordisk on High Drug Costs for Diabetes and Obesity Treatments

Senator Sanders Takes a Stand on Drug Pricing

During a recent Senate Health Committee hearing, U.S. Senator Bernie Sanders expressed profound concerns over the inflated prices of diabetes and obesity drugs, particularly Ozempic and Wegovy. For over two hours, Sanders and fellow lawmakers scrutinized Novo Nordisk CEO Lars Jorgensen, demanding equitable pricing for these critical medications.

Cost Disparities Highlighted

Sanders highlighted astonishing pricing differences, noting that in the U.S., Ozempic costs about $969, compared to just $59 in Germany. Similarly, Wegovy is priced at $1,349 in the U.S., while it is only $92 in the UK. 'If not made affordable, Americans throughout this country will needlessly die and suffer,' Sanders stated vehemently.

Insurance Coverage and Accessibility

• Jorgensen defended his company's pricing policies, citing a 40% drop since Ozempic was launched.
• He also mentioned that 99% of commercial insurance plans cover Ozempic, including Medicare and Medicaid.
• Currently, 80% of insured Americans can access their medications for $25 or less per month.

Ongoing Negotiations for Fair Pricing

Despite these assertions, Senator Sanders remains adamant, stating that he has gained support from major pharmacy benefit managers (PBMs) to enhance coverage if Novo Nordisk minimizes its list prices. With approximately 72% of Novo Nordisk's revenue generated from the U.S., the pressure for reform intensifies.

As lawmakers continue to scrutinize pharmaceutical pricing, the hope is for a resolution that prioritizes patient care and affordability for necessary treatments.